` RUA (Rua Life Sciences PLC) vs FTSE All Share Index Comparison - Alpha Spread

RUA
vs
FTSE All Share Index

Over the past 12 months, RUA has outperformed FTSE All Share Index, delivering a return of -2% compared to the FTSE All Share Index's 0% growth.

Stocks Performance
RUA vs FTSE All Share Index

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
RUA vs FTSE All Share Index

Loading
RUA
FTSE All Share Index
Difference

Performance By Year
RUA vs FTSE All Share Index

Loading
RUA
FTSE All Share Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Rua Life Sciences PLC vs Peers

FTSE All Share Index
RUA
7741
ALC
COLO B
ALGN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Rua Life Sciences PLC
Glance View

Market Cap
7.5m GBX
Industry
Health Care

RUA Life Sciences Plc is a holding company, which engages in the commercialization of biomedical polymer technology, components, and medical devices. The company is headquartered in Ayrshire, Ayrshire and currently employs 32 full-time employees. The firm is a manufacturer of medical devices and licensor of its IP and know-how together with developing medical devices utilizing its polymer IP. The firm operates through four businesses. Its RUA Medical business provides sub-contract manufacturing, assembly, packing and services to the medical device sector from its Class seven and eight cleanroom suites. Its RUA Biomaterials is the depository of the IP and licensing rights to a range of biostable, implantable polymers, including Elast-EonTM and ECSilTM. Its RUA Vascular business is the legal manufacturer and IP holder of the Company’s cardiovascular and soft tissue patches and bore vascular grafts. Its RUA Structural Heart business holds the intellectual property relating to the Company’s synthetic heart valve technology.

RUA Intrinsic Value
10.35 GBX
Overvaluation 14%
Intrinsic Value
Price
Back to Top